Show simple item record

CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.

dc.contributor.authorGilham, David E
dc.contributor.authorDebets, R
dc.contributor.authorPule, M
dc.contributor.authorHawkins, Robert E
dc.contributor.authorAbken, Hinrich
dc.date.accessioned2012-11-09T14:26:42Z
dc.date.available2012-11-09T14:26:42Z
dc.date.issued2012-07
dc.identifier.citationCAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. 2012, 18 (7):377-84 Trends Mol Meden_GB
dc.identifier.issn1471-499X
dc.identifier.pmid22613370
dc.identifier.doi10.1016/j.molmed.2012.04.009
dc.identifier.urihttp://hdl.handle.net/10541/251564
dc.description.abstractRecent reports on the impressive efficacy of adoptively transferred T cells to challenge cancer in early phase clinical trials have significantly raised the profile of T cell therapy. Concomitantly, general expectations are also raised by these reports, with the natural aspiration to deliver this therapy over a wide range of tumor indications. Chimeric antigen receptors (CARs) endow T cell populations with defined antigen specificities that function independently of the natural T cell receptor and permit targeting of T cells towards virtually any tumor. Here, we review the current clinical application of CAR-T cells and relate clinical efficacy and safety of CAR-T cell trials to parameters considered critical for CAR engineering, classified as the three T's of CAR-T cell manipulation.
dc.language.isoenen
dc.rightsArchived with thanks to Trends in molecular medicineen_GB
dc.subject.meshAdoptive Transfer
dc.subject.meshAnimals
dc.subject.meshAntigens, Neoplasm
dc.subject.meshHumans
dc.subject.meshNeoplasms
dc.subject.meshReceptors, Antigen, T-Cell
dc.subject.meshRecombinant Fusion Proteins
dc.subject.meshT-Lymphocytes
dc.titleCAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.en
dc.typeArticleen
dc.contributor.departmentClinical and Experimental Immunotherapy Group, School of Cancer and Enabling Sciences, The University of Manchester, Withington, Manchester M20 4BX, UK. dgilham@picr.man.ac.uken_GB
dc.identifier.journalTrends in Molecular Medicineen_GB
html.description.abstractRecent reports on the impressive efficacy of adoptively transferred T cells to challenge cancer in early phase clinical trials have significantly raised the profile of T cell therapy. Concomitantly, general expectations are also raised by these reports, with the natural aspiration to deliver this therapy over a wide range of tumor indications. Chimeric antigen receptors (CARs) endow T cell populations with defined antigen specificities that function independently of the natural T cell receptor and permit targeting of T cells towards virtually any tumor. Here, we review the current clinical application of CAR-T cells and relate clinical efficacy and safety of CAR-T cell trials to parameters considered critical for CAR engineering, classified as the three T's of CAR-T cell manipulation.


Files in this item

This item appears in the following Collection(s)

Show simple item record